Story perspectives

Wegovy Cuts Heart Risk by 57%, Boosts Novo Nordisk Stock

9/1/2025

30 2

Summary

Story summary

A study shows Novo Nordisk's Wegovy lowers heart attack and stroke risk by 57% compared to Eli Lilly's Mounjaro and Zepbound.
The results, derived from real-world data, suggest Wegovy's heart benefits may not extend to all GLP-1 drugs.
Novo Nordisk's stock increased by 3% post-announcement, though analysts advise caution in interpreting the findings.
Denmark revised its economic growth forecast downward, influenced by Novo's decreasing market share in the U.S.

1 of 1

Story summary

A study shows Novo Nordisk's Wegovy lowers heart attack and stroke risk by 57% compared to Eli Lilly's Mounjaro and Zepbound.
The results, derived from real-world data, suggest Wegovy's heart benefits may not extend to all GLP-1 drugs.
Novo Nordisk's stock increased by 3% post-announcement, though analysts advise caution in interpreting the findings.
Denmark revised its economic growth forecast downward, influenced by Novo's decreasing market share in the U.S.